Results 151 to 160 of about 65,591 (261)

Urine‐Based Bladder Cancer Diagnostics: A Local Evaluation of Cxbladder and Review of the ANZ Landscape

Trends in Urology &Men's Health, Volume 17, Issue 2, April 2026.
ABSTRACT The high demand for cystoscopies performed for bladder cancer diagnosis or surveillance imposes a significant burden on regional centres with limited capacity. Cxbladder is a urinary biomarker test that estimates the likelihood of bladder cancer.
Claris Oh, Kim Tien Chah, Kian Lotter, Steven Lun, Manuel Yuhico   +4 more
wiley   +1 more source

Recurrent Bladder Urothelial Carcinoma [PDF]

, 2020
openaire   +1 more source

KRAB Zinc‐Finger Protein ZNF205 Promotes Hepatocellular Carcinoma via p53 Pathway Repression

Cancer Science, Volume 117, Issue 4, Page 1057-1071, April 2026.
ZNF205 functions as a critical oncogenic regulator in hepatocellular carcinoma (HCC), where it interacts with p53 and functionally suppresses its transcriptional activity by competitively inhibiting p53 binding to target gene promoters. This p53 inactivation mechanism critically contributes to tumor progression in HCC. ABSTRACT The tumor suppressor p53
Xiaofen Huang, Yingchuan Yang, Yuan Ma, Wei Hao, Jingzhuo Jin, Yue Ding, Yiming Zhang, Xiuyuan Zhang, Xinli Li, Qin Song, Jiaqi Liu, Bingxin Liu, Yuanjun Zhai, Chunling Zhao, Jin Wu, Chunyan Tian   +15 more
wiley   +1 more source

Metastatic Bladder Urothelial Carcinoma [PDF]

, 2020
openaire   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment. [PDF]

Int J Mol Sci
Jiang H, Chen Y, Zeng X, Yang R, Zhang F, Zhang H, Zhang E, Wu X, Yan D, Yu C.   +9 more
europepmc   +1 more source

Regulation of drug resistance in bladder urothelial carcinoma by tumor aerobic glycolysis. [PDF]

J Transl Med
Weng C, Deng H, Yang Z, Zeng X, Xu H, Li J, Yu C.   +6 more
europepmc   +1 more source

Neoadjuvant immunotherapy combined with HER2-targeted antibody-drug conjugate in bladder urothelial carcinoma: a case report. [PDF]

BMC Urol
Guo Z, Wang G.
europepmc   +1 more source

Establishment of a canine urothelial carcinoma‐derived organoid biobank: A platform for comparative and translational research

Clinical and Translational Medicine, Volume 16, Issue 4, April 2026.
Christopher Zdyrski, Aleksandra Pawlak, Hannah F. Nicholson, Megan P. Corbett, Michael Catucci, John Cheville, Haejin Cho, Bryan J. Melvin, Jiayi Peng, Corey Saba, Hayden Hamsher, Steven G. Friedenberg, Andrew P. Woodward, Eugene Douglass, Jonathan P. Mochel, Karin Allenspach   +15 more
wiley   +1 more source

Multivesicular body subunit 12B (MVB12B) overexpression represses proliferation and migration in bladder urothelial carcinoma. [PDF]

Transl Cancer Res
Li X, Cen C, Li R, Su Q, Mo W, Lin F.
europepmc   +1 more source